Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$12.52 USD
+1.54 (14.03%)
Updated Sep 9, 2024 10:00 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Travere Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 145 | 212 | 227 | 198 | 175 |
Cost Of Goods | 11 | 8 | 7 | 6 | 5 |
Gross Profit | 134 | 204 | 221 | 192 | 170 |
Selling & Adminstrative & Depr. & Amort Expenses | 522 | 471 | 382 | 368 | 307 |
Income After Depreciation & Amortization | -388 | -267 | -162 | -176 | -137 |
Non-Operating Income | 23 | 0 | 2 | 6 | 10 |
Interest Expense | 11 | 11 | 20 | 19 | 19 |
Pretax Income | -376 | -278 | -180 | -189 | -146 |
Income Taxes | 0 | 0 | 0 | -19 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -376 | -278 | -180 | -169 | -146 |
Extras & Discontinued Operations | 265 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -111 | -278 | -180 | -169 | -146 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -355 | -232 | -122 | -140 | -82 |
Depreciation & Amortization (Cash Flow) | 33 | 35 | 40 | 36 | 55 |
Income After Depreciation & Amortization | -388 | -267 | -162 | -176 | -137 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 74.27 | 63.76 | 59.83 | 47.54 | 42.34 |
Diluted EPS Before Non-Recurring Items | -5.07 | -4.37 | -3.01 | -3.56 | -3.46 |
Diluted Net EPS (GAAP) | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 |
Fiscal Year end for Travere Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 54.12 | 41.37 | -8.55 | 37.10 | 59.70 |
Cost Of Goods | 2.06 | 1.50 | 3.05 | 1.29 | 1.99 |
Gross Profit | 52.06 | 39.87 | -11.59 | 35.81 | 57.71 |
SG&A, R&D, and Dept/Amort Expenses | 119.76 | 179.11 | 106.54 | 128.39 | 145.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | -67.70 | -139.24 | -118.13 | -92.58 | -87.58 |
Non-Operating Income | 0.93 | 6.27 | 8.53 | 6.18 | 4.93 |
Interest Expense | 2.79 | 2.80 | 2.66 | 2.82 | 2.91 |
Pretax Income | -69.57 | -135.77 | -115.06 | -89.23 | -85.57 |
Income Taxes | 0.09 | 0.19 | 0.07 | 0.01 | 0.07 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -69.65 | -135.96 | -115.13 | -89.24 | -85.63 |
Extras & Discontinued Operations | -0.76 | -0.10 | 24.96 | 239.98 | 0.00 |
Net Income (GAAP) | -70.41 | -136.06 | -90.17 | 150.74 | -85.63 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 77.50 | 77.14 | 76.48 | 76.31 | 76.00 |
Diluted EPS Before Non-Recurring Items | -0.90 | -1.76 | -1.16 | -1.17 | -1.13 |
Diluted Net EPS (GAAP) | -0.91 | -1.76 | -1.07 | 1.97 | -1.13 |